Resources

Novel Coronavirus (COVID-19) Physician Tracking Report – Wave 6

Since January, InCrowd has been conducting novel coronavirus (COVID-19) tracking research to understand the impact of the pandemic on several US healthcare stakeholder groups. Now in its fifth wave, InCrowd has been monitoring frontline-treating physicians’ perceptions on the spread of the virus, preparedness, a variety of concerns, and how they envision both pharma engagement and care delivery in the future. Discover the latest findings and insights from InCrowd’s most recent wave of COVID-19 physician research.

Methodology:

  • Method: 12-minute MicroSurvey via InCrowd
  • Crowds: US Primary Care Physicians (PCPs), Pediatricians (PEDs), and Emergency Medicine or Critical Care Physicians (EMCCs)
  • Sample Size: n=211
  • Fielding Period: June 26, 2020 (Previous Waves: May 29-31, Apr. 14-15, Mar. 19-20, Feb. 26-27, Jan. 31-Feb. 4)

InCrowd’s other COVID-19 Tracking Reports:

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

The Impact of Technology on Mental Healthcare

The Impact of Technology on Mental Healthcare

Exploring Psychiatrist Opinions and Expectations Around the Rise in Digital Therapeutics to Treat Mental Health The National Institutes of Health (NIH) believe “technology has opened a new frontier in mental health support,” but questions remain around how...

read more
ESMO 2022 Real-Time Roundup

ESMO 2022 Real-Time Roundup

The 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) took place in person from September 9th to the 13th. InCrowd wanted to learn from those Medical Oncologists and Hematology-Oncologists who attended the following two objectives: Explore which...

read more
ASCO 2022 Real-Time Roundup

ASCO 2022 Real-Time Roundup

The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in person from June 3rd to the 7th. InCrowd wanted to learn from those oncologists who attended the following two objectives: Explore which tumor type/track had the most exciting...

read more